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The isolation of islets by collagenase digestion can cause damage and impact the efficiency of islet engraft-
ment and function. In this study, we assessed the basement membranes (BMs) of mouse pancreatic islets as a 
molecular biomarker for islet integrity, damage after isolation, and islet repair in vitro as well as in the absence 
or presence of an immune response after transplantation. Immunofluorescence staining of BM matrix proteins 
and the endothelial cell marker platelet endothelial cell adhesion molecule-1 (PECAM-1) was performed on 
pancreatic islets in situ, isolated islets, islets cultured for 4 days, and islet grafts at 3–10 days posttransplanta-
tion. Flow cytometry was used to investigate the expression of BM matrix proteins in isolated islet b-cells. The 
islet BM, consisting of collagen type IV and components of Engelbreth–Holm–Swarm (EHS) tumor laminin 
111, laminin a2, nidogen-2, and perlecan in pancreatic islets in situ, was completely lost during islet isolation. 
It was not reestablished during culture for 4 days. Peri- and intraislet BM restoration was identified after islet 
isotransplantation and coincided with the migration pattern of PECAM-1+ vascular endothelial cells (VECs). 
After islet allotransplantation, the restoration of VEC-derived peri-islet BMs was initiated but did not lead to 
the formation of the intraislet vasculature. Instead, an abnormally enlarged peri-islet vasculature developed, 
coinciding with islet allograft rejection. The islet BM is a sensitive biomarker of islet damage resulting from 
enzymatic isolation and of islet repair after transplantation. After transplantation, remodeling of both peri- and 
intraislet BMs restores b-cell–matrix attachment, a recognized requirement for b-cell survival, for isografts but 
not for allografts. Preventing isolation-induced islet BM damage would be expected to preserve the intrinsic 
barrier function of islet BMs, thereby influencing both the effector mechanisms required for allograft rejection 
and the antirejection strategies needed for allograft survival.
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InTRoducTIon
The vast improvement in islet transplant survival and 
function using the steroid-free Edmonton protocol of 
immunosuppression or variations of it (10,14,15,43,44) 
has led to a resurgence in the clinical transplantation of 
islets for the treatment of insulin-dependent or type 1 dia-
betes. Nevertheless, because of the heavy immunosuppres-
sion required, the criteria for patient selection have largely 
been restricted to the persistence of brittle diabetes and 
ineffective insulin therapy. Excessive numbers of islets 
(up to 10,000 islet equivalents per kilogram body weight) 
have been used to alleviate the need for insulin treatment 
of transplantation patients, and usually this has dictated 
the necessity for multiple islet donors (15) and stringent 
donor selection (15,43). Even then, long-term normogly-
cemia (> 5 years) is not consistently achieved (10,15,43). 
Factors contributing to these problems include islet dam-
age and loss of viability due to bystander effects of the 
enzymatic digestion of the donor pancreas, the impact of 
hypoxia on islet survival before islet revascularization after 
transplantation, long-term toxic effects of immunosuppres-
sion, and autoimmune damage and/or allograft rejection. 
Experimental studies have revealed that the isolation pro-
cess results in loss of islet innervation (36), disruption of 
islet microvasculature (18), and apoptosis of b-cells due to 
significant loss of intracellular stores of the glycosamino-
glycan heparan sulfate (57) and to detachment from the 
extracellular matrix (ECM) (50,51,55). It is generally 
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accepted that such changes to islet architecture negatively 
impact islet survival and function early after transplanta-
tion and necessitate the transfer of excessive numbers of 
islets to compensate for this loss.
Efforts to minimize damage of human islets by over-
digestion of the pancreas are currently focused on the criti-
cal assessment of cocktails of collagenolytic and proteolytic 
enzymes (1,2,10,15,16,30,43). Indeed, previous studies 
reported that mantled islets isolated with a rim of acinar 
tissue attached to the islet periphery (40) functioned signif-
icantly better than highly purified islets (51). This improve-
ment was attributed to the retention of islet- associated 
ECM or islet basement membrane (BM), and thus the pre-
vention of matrix detachment-induced apoptosis (anoikis) 
(12,50). In contrast, analyses of individual matrix proteins 
have revealed that purified islets lack peripheral staining 
for laminin (37,54,55) and collagen (37,54,55), supporting 
the notion that islets lose their BM during the isolation pro-
cess (11,50). Such studies, however, have been incomplete 
and largely disadvantaged by the unavailability of appro-
priate reagents. Recently, we confirmed that mouse islets 
in situ are surrounded by a continuous BM comprising all 
of the conventional matrix protein components: laminin, 
collagen type IV, nidogen, and the heparan sulfate proteo-
glycan (HSPG) perlecan (17). This was a significant find-
ing because the HSPG constituent, in particular, provides 
BMs with a barrier function that prevents cell invasion (33) 
and hence represents an intrinsic defense mechanism for 
islets in situ (17,57).
In addition to providing a barrier function, BMs also 
provide structural support for adjacent cells and play a role 
in separating tissues into different compartments (23,35). 
In particular, the islet BM provides a source of special-
ized ECM to which islet cells located at the periphery can 
attach via integrin–matrix protein interactions (23,37,54). 
Pancreatic islets in situ are highly vascularized, and cross-
sections show that each intraislet capillary is surrounded 
by 8–10 islet b-cells (4,31), suggesting that the vascu-
lar endothelial BM within islets may also function as an 
ECM for attachment of islet cells located more distantly 
from the islet boundary and within the islet core (28). The 
previous report of a “double BM” surrounding capillaries 
within human islets in situ also supports this notion (53). 
In any case, it is reasonable to predict that an islet isola-
tion process that disrupts both the islet BM and intraislet 
vascular endothelial BM is likely to lead to extensive islet 
cell apoptosis or anoikis due to matrix detachment.
In this study, we set out (i) to examine a panel of islet BM 
matrix proteins (laminins, collagen type IV, nidogen, and 
perlecan) in isolated mouse islets and compared this profile 
with the status before their isolation, after culture, and after 
transplantation; (ii) to ascertain the potential for BM repair 
in islets in vitro and after transplantation; (iii) to identify 
a mechanism of BM recovery; and (iv) to investigate the 
likely impact of BM remodeling on islet engraftment and 
b-cell–matrix attachment in islet isografts and during 
allograft rejection. Our studies reveal that islet isolation 
induces dramatic loss of the islet BM. We observed com-
plete repair of the islet BM only after isotransplantation, 
a process that is most likely due to vascular endothelial 
cells (VECs). Recovery of islet BMs was often incomplete 
after allotransplantation. Such partial repair of the barrier 
function of islet BMs would render the islets highly vulner-
able to mononuclear cell (MNC) invasion during rejection. 
These findings highlight the islet BM as a critical bio-
marker for islet integrity in vitro and in vivo.
MATeRIALs And MeThods
Animals
CBA (H-2k) and C57BL/6 (H-2b) male mice, 6–13 weeks 
old, were obtained from the Australian National University 
Bioscience Facility, Canberra, Australia, and Monash 
University, Melbourne, Australia, for pancreas harvest 
and islet isolation and as recipients of islet transplants. All 
experiments performed with mice were approved by the 
Australian National University Animal Experimentation 
Ethics Committee.
Cell Lines
The PFHR-9 cell line, derived from a mouse embryonal 
carcinoma, was obtained from Professor Erik Thompson 
(St Vincent’s Institute of Medical Research, Melbourne, 
Australia) and maintained in culture in Dulbecco’s modi-
fied Eagle medium (DMEM) supplemented with 25 mM 
glucose (Cat. No. 11995; Gibco/Invitrogen, Carlsbad, CA, 
USA), 10% fetal calf serum (SAFC Biosciences, Bunbury, 
Western Australia, Australia), and antibiotics [penicillin 
G (Cat. No. 156065; MP Biomedicals, Santa Ana, CA, 
USA), streptomycin sulfate (Cat. No. S6501; Sigma-
Aldrich, St. Louis, MO, USA), neomycin sulfate (Cat. No. 
N-6386; Sigma-Aldrich)] in a humidified gas phase of 5% 
CO2 in air. Adherent PFHR-9 cells were harvested using 
0.05% ethylenediaminetetraacetic acid (EDTA; Cat. No. 
10093.5V; BDH Chemicals, Kilsyth, Victoria, Australia) 
and transferred to individual wells of CELLSTAR 96-well 
plates (Greiner Bio-one, Frickenhausen, Germany) at 
2 × 105/well for intracellular staining of matrix proteins and 
analysis by flow cytometry.
Islet Isolation
Islets were isolated as previously described (9,46). 
Briefly, islets were isolated from groups of five anesthe-
tized donor CBA or C57BL/6 mice {0.025 ml Avertin/g 
body weight [70 mM 2,2,2-tribomoethanol; Cat. No. 
T48402, Sigma-Aldrich, in 2% (v/v) 2-methyl-2-2 buta-
nol; Fluka Chemie AG, Buch, Switzerland]} by initially 
perfusing the pancreas in situ via the common bile duct 
with 2.5 mg/ml of collagenase P (Roche Diagnostics, 
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Mannheim, Germany). The inflated pancreas was digested 
further with an additional 2.5 mg/ml of collagenase P in a 
stationary water bath at 37°C. The digest was then shaken 
briefly by hand, vortexed lightly, placed on ice to termi-
nate enzymatic digestion, and washed. Islets were hand-
picked from the digested pancreas tissue with the aid of 
a dissecting microscope (Kyowa Optical SDZ-P, Tokyo, 
Japan). Isolated islets were either immediately frozen in 
liquid Forane® refrigerant preequilibrated in liquid nitro-
gen (134a; Arkema Inc., King of Prussia, PA, USA) or 
transplanted.
b-Cell Isolation
CBA mouse islets were dispersed into single-cell sus-
pensions using 1 mg/ml Dispase II (Roche) in chelation 
buffer, as previously described (57). Islet b-cells (3–4 × 104) 
were transferred to individual wells of CELLSTAR 96-well 
plates (Greiner Bio-one) in Roswell Park Memorial Institute 
(RPMI) 1640 medium (Gibco/Invitrogen) supplemented 
with 10% fetal calf serum for immunofluorescence stain-
ing of matrix proteins and analysis by flow cytometry.
Islet Transplantation 
Islets prepared from CBA donors were transplanted as 
isografts and allografts to CBA and C57BL/6 recipient 
mice, respectively; C57BL/6 islets were also transplanted 
to C57BL/6 and CBA mice as isografts and allografts, 
respectively. To aid transplantation, isolated mouse islets 
were embedded in blood clots prepared from the recipi-
ent mouse strain’s blood (50–100 adult islets per clot, 250 
islets per transplant). The islets contained in blood clots 
(three clots per graft) were transplanted beneath the kid-
ney capsule of recipient mice anesthetized with Avertin 
(0.012 ml/g body weight intraperitoneally), as previously 
described (45,46). Transplant recipients were killed by cer-
vical dislocation at 3, 5, 7, or 10 days posttransplant. Grafts 
were frozen in liquid Forane 134a (preequilibrated with 
liquid nitrogen), embedded in OCT compound (Cat. No. 
1A018; ProSciTech, Thuringowa, Queensland, Australia), 
and stored at −70°C until frozen sectioning and staining.
Immunofluorescence Staining of Tissue Sections and 
Analysis by Microscopy
Immunohistochemistry was performed as previously 
described (17). Tissue sections (10 μm) were prepared 
using a CM1800 Leica cryostat (Adeal, Altona North, 
Victoria, Australia), collected on Superfrost glass slides 
(HD Scientific Supplies, Glengala, Victoria, Australia), 
and stored at −20°C until use. The antibodies used for 
immunohistochemistry and the relevant fixation condi-
tions are summarized in Table 1. Unfixed sections were 
dried under vacuum for 5 min, followed by fixation in 
either formalin (Cat. No. FO00112500; Chem-Supply Pty 
Ltd, Gillman, South Australia, Australia) or 100% ethanol 
(Cat. No. EA043-10L-P; Chem-Supply Pty Ltd) (Table 1). 
Sections were then rinsed in 3 × 5-min changes of hyper-
tonic phosphate-buffered saline [10 mmol/L sodium/
potassium phosphate (Cat. No. P5379; Sigma-Aldrich 
Pty Ltd, Castle Hill, New South Wales, Australia) with 
0.274 mol/L NaCl [Cat. No. 131659.1214; Panreac/
Pure Science Ltd, Plimmerton, Porirua, New Zealand] 
and 5 mmol/L KCl (Cat. No. 383; Ajax Finechem Pty 
Ltd, Seven Hills, New South Wales, Australia); pH 7.2] 
before treatment with blocking solution (10% v/v normal 
donkey serum; Sigma-Aldrich) in antibody diluent contain-
ing 0.55 mol/L NaCl and 10 mmol/L sodium phosphate 
(Monobasic: Cat. No. S8282, Dibasic: Cat. No. S7907; 
Sigma-Aldrich Pty Ltd; pH 7.1) for 20 min at room tem-
perature. Incubation with primary antibodies was carried 
out overnight at room temperature. Secondary antibod-
ies (Jackson ImmunoResearch Laboratories, West Grove, 
PA, USA) used to localize components of Engelbreth–
Holm–Swarm tumor (EHS) laminin 111 and nidogen-2 
were donkey anti-rabbit IgG conjugated to fluorescein 
(1:100; Cat. No. 711-096-152) and cyanine 3 (Cy3; 1:100; 
Cat. No. 711-166-152), respectively. For detecting dual 
Table 1. Primary Antibodies and Fixation Conditions Used for Immunoflourescence Staining
Antigen (Species)
Primary Antibody
Source Dilution FixationHost Species Code
Laminin a2 (mouse) Rat 4H8-2 Sigma Chemical, Castle Hill, NSW, Australia 1:3200 Formalin
Type IV collagen (mouse) Rabbit T40263R Biodesign, Meridian Life Science, Memphis, 
TN, USA
1:100 Formalin
Laminin EHS (mouse) Rabbit L9393 Sigma Chemical 1:100 100% Ethanol
Nidogen-2 (mouse) Rabbit Ab14513 Abcam, Cambridge, UK 1:800 Formalin
Perlecan (mouse) Rabbit 906 Dr. Dziadeka (8) 1:800 100% Ethanol
PECAM-1/CD31 Rat 390 BD Pharmingen/BD Bioscience, North Ryde, 
NSW, Australia
1:500 100% Ethanol
aM. Dziadek, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
EHS, Engelbreth–Holm–Swarm tumor; PECAM-1/CD31, platelet endothelial cell adhesion molecule-1/cluster of differentiation 31.
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localizations of laminin a2 and collagen type IV, and per-
lecan and platelet endothelial cell adhesion molecule-1 
(PECAM-1), secondary antibodies were donkey anti-rat 
IgG conjugated to Cy3 (1:100; Cat. No. 715-165-153) 
and biotin-SP-conjugated Affinipure donkey anti-rabbit 
IgG followed by fluorescein-conjugated streptavidin 
(1:100; Cat. No. 016-090-084). Sections were treated with 
100 mM 4¢,6-diamidino-2-phenylindole dihydrochloride 
(DAPI) (Molecular Probes, Eugene, OR, USA) to iden-
tify nuclei, and coverslips (Cat. No. HDLD22401-01P0; 
HD Scientific Supplies Pty Ltd, Wetherill Park, New 
South Wales, Australia) were attached with mounting 
medium for fluorescence microscopy (Dako Corporation, 
Carpinteria, CA, USA). Sections were observed and pho-
tographed with an Olympus BX50 microscope with an 
epifluorescence attachment and a Spot RT digital camera 
(Diagnostic Instruments, Sterling Heights, MI, USA). For 
light microscopy, frozen sections were fixed in formalin 
and stained with hematoxylin and eosin (H&E) (Cat. No. 
GHS232 and HT11033; Sigma-Aldrich Pty Ltd.). 
Flow Cytometry 
For intracellular staining, isolated b-cells (prepared from 
islets harvested from groups of five donor mouse pancre-
ases) and PFHR-9 cells were first fixed and permeabilized 
using the BD Cytofix/Cytoperm Fixation/Permeabilization 
Kit (BD Pharmingen/BD Biosciences, San Jose, CA, USA). 
The cells were then stained with polyclonal rabbit anti-
EHS laminin (Sigma-Aldrich), anti-mouse collagen type 
IV (AbD Serotec, Kidlington, Oxfordshire, UK), anti-
mouse nidogen-2 (Abcam, Cambridge, UK), or anti-
mouse perlecan (Dr. Dziadek, Sydney, Australia), followed 
by phycoerythrin (PE)-donkey anti-rabbit IgG (Jackson 
ImmunoResearch, West Grove, PA, USA). Rabbit IgG 
(Southern Biotech, Birmingham, AL, USA) was used as 
the isotype control IgG. The geometric mean fluorescence 
ratio (GMFR) was calculated by dividing the geometric 
mean fluorescence intensity (GMFI) of cells stained with 
primary antibody by the GMFI of cells stained with the 
isotype control IgG (57). Cells were analyzed using a BD 
LSRI flow cytometer and CellQuest™ software (version 
6.0, BD Biosciences).
ResuLTs
Localization of BM Matrix Proteins in Islets  
In Situ and In Vitro
Immunofluorescence staining of normal CBA islets in 
situ in the pancreas (Figs. 1–3), as previously reported 
for insulitis-free nonobese diabetic (NOD)/Lt islets (17), 
confirmed that a continuous islet BM consisting of per-
lecan (Fig. 1A), collagen type IV (Fig. 1B), laminin a2 
(Fig. 1B), components of EHS laminin 111 (Fig. 2C), and 
nidogen-2 (Fig. 2D) was localized at the islet periphery. 
These studies further indicated that laminin a2 was more 
strongly associated with the BM of pancreatic acini than 
with the islet BM (Fig. 1B). Because a double BM has 
previously been reported for the intraislet blood vessels 
of human islets but not mouse islets (53), colocalization 
of perlecan with PECAM-1-positive VECs of intraislet 
capillaries and peri-islet blood vessels was identified as 
the subvascular endothelial BM (Fig. 1A). This vascular 
endothelial BM also stained strongly for collagen type 
IV (Fig. 1B), components of EHS laminin 111 (Fig. 2C), 
and nidogen-2 (Fig. 2D) but showed weak localization of 
laminin a2 (Fig. 1B).
In contrast to islets in situ, freshly isolated CBA islets 
in vitro revealed substantial damage to the islet BM, with 
loss of perlecan (Fig. 1C), collagen type IV (Fig. 1D), 
components of EHS laminin 111 (Fig. 2G), and nidogen-2 
(Fig. 2H) and extensive disruption of laminin a2 (Figs. 1D 
and 2F). In contrast, residual intraislet vascular BM was 
characterized by retention of perlecan (Fig. 1C), collagen 
type IV (Fig. 1D), EHS laminin (Fig. 2G), and nidogen-2 
Figure 1. Pancreatic islet basement membrane (BM) is lost 
during islet isolation and does not recover after in vitro culture. 
CBA mouse islets in situ in the pancreas (A, B), freshly isolated 
(C, D), or after 4 days in vitro culture (E, F) were examined by 
immunofluorescence microscopy for their content and distribu-
tion of perlecan (green fluorescence), platelet endothelial cell 
adhesion molecule-1 (PECAM-1; red fluorescence), collagen 
type IV (green fluorescence), and laminin a2 (red fluorescence). 
Yellow fluorescence represents sites where green and red fluo-
rescence colocalize. The islet BM in situ in A and B is identified 
by peri-islet staining for perlecan, collagen type IV, and laminin 
a2 (arrows). Colocalization of perlecan and PECAM-1 identi-
fied some subendothelial BM at the islet periphery and within 
the islets in situ in the pancreas (A). Nuclei are counterstained 
blue with 4¢,6-diamidino-2-phenylindole  dihydrochloride (DAPI). 
Arrows indicate location of islet BM. Scale bars: 25 μm.
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(Fig. 2H) but little, if any, laminin a2 (Fig. 1D). There was 
no evidence of recovery of the islet BM during in vitro 
culture of the islets for 4 days (Fig. 1E, F), and the lumen 
of intraislet capillaries, which was characteristic of freshly 
isolated islets (Fig. 1C, D), was no longer clearly evident. 
Instead, there appeared to be isolated and diffuse staining 
for matrix proteins within the islets (Fig. 1E, F) associated 
with residual PECAM-1+ VECs (Fig. 1E). This find-
ing raised the possibility that in vitro, surviving intraislet 
endothelial cells were secreting matrix proteins de novo. 
The islet BM also failed to be restored in vitro after pro-
longed culture of the islets for 7 days (data not shown). 
However, central necrosis, which was more prominent 
within the islets after 7 days of culture, compared with 4-day 
cultured islets, indicated a deterioration in islet viability.
Recovery of Peri-Islet BM and Intraislet Vascular BM 
After Islet Isotransplantation
Unlike isolated CBA islets (Figs. 1C, D; 2E−H; and 
3D−F) and islets maintained in culture (Fig. 1E, F), 
Figure 2. Complete reconstitution of the islet BM occurs over a 10-day period in islet isografts transplanted under the kidney capsule. 
Collagen type IV, laminin a2, components of Engelbreth–Holm–Swarm tumor (EHS) laminin 111, and nidogen-2 were localized by 
immunofluorescence staining in CBA islets in situ in the pancreas (A–D), CBA isolated islets (E–H), and in CBA islet isografts at day 
3 (I–L), day 5 (M–P), day 7 (Q–T), and day 10 (U–X) posttransplant. Nuclei are counterstained blue with DAPI. M and N, Q and R, 
and U and V show dual localization of collagen type IV and laminin a2, respectively, whereas K and L, O and P, and S and T show 
localization of components of EHS laminin 111 and nidogen-2 on adjacent sections. *Invaginations into the islets. Scale bars: 25mm.
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isogeneic CBA islets engrafted beneath the kidney cap-
sule of CBA recipient mice [which do not mount a rejec-
tion response due to the cells being genetically identical 
to the donor islets at both the major histocompatibility 
complex (MHC) and non-MHC loci] exhibited recovery 
of the islet BM. Deposition of collagen type IV (Fig. 2I), 
laminin a2 (Fig. 2J), EHS laminin (Fig. 2K), nidogen-2 
(Fig. 2L), and perlecan (Fig. 3G) was evident at day 3 
posttransplant, but the staining was incomplete and often 
diffuse around the periphery of the islets. Staining of 
Figure 3. Recovery of the islet BM after transplantation and revascularization of the engrafted islets correlates with the migration of 
PECAM-1+ VECs. CBA islets in situ in the pancreas (A–C), CBA isolated islets (D–F), and CBA islet isografts at day 3 (G–I), day 5 
(J–L), day 7 (M–O), and day 10 (P–R) posttransplant were analyzed by fluorescence staining for the localization of perlecan and the 
endothelial cell marker PECAM-1. Merged images of perlecan (A, D, G, J, M, P) with PECAM-1 (B, E, H, K, N, Q), respectively, are 
also shown (C, F, I, L, O, R). Recovery of peri-islet perlecan at 3–5 days after transplantation (G, J) correlated with continuous peri-
islet expression of PECAM-1 (H, K). Perlecan (M, P) and PECAM-1 (N, Q) staining coinvaginated into the engrafted islets by 7–10 
days posttransplant (arrows in M, N, O and asterisks in P, Q, R). Although continuous peri-islet PECAM-1 staining had disappeared by 
day 7 posttransplant (N), uninterrupted peri-islet perlecan staining remained at 7–10 days (M, P), representing the newly formed islet 
BM. Nuclei are counterstained blue with DAPI. Scale bars: 25 μm.
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matrix proteins at 5 to 7 days posttransplant revealed 
further peri-islet remodeling and organization (Fig. 2M, 
O−Q, S, T; Fig. 3J, M) with the exception of laminin a2 
(Fig. 2N, R), which reappeared more slowly. At day 7 
posttransplant, collagen type IV, components of EHS 
laminin 111 and nidogen-2 were localized within the 
islets and appeared to be invaginations from the islet 
periphery (Fig. 2Q, S, T). By day 10, the peri-islet BMs 
showed complete reconstitution with continuous staining 
for the proteins, collagen type IV (Fig. 2U), laminin a2 
(Fig. 2V), components of EHS laminin 111 (Fig. 2W), 
nidogen-2 (Fig. 2X), and perlecan (Fig. 3P). 
In parallel with the disorganized deposition of BM 
matrix proteins at the periphery of engrafted islets on 
day 3, we observed discontinuous peri-islet staining for 
PECAM-1 (a marker for VECs), suggesting that VECs had 
migrated to peri-islet sites (Fig. 3H). The intraislet local-
ization of perlecan (Fig. 3G) at day 3 also correlated with 
localization of intraislet staining for PECAM-1 (Fig. 3H, 
I), defining vascular endothelial BM that may have been 
derived from the isolated donor islets (Fig. 3D, E). The 
colocalization of perlecan and PECAM-1 staining, which 
was continuous around the periphery of islets by day 5 
(Fig. 3J, K, L), strongly suggested that the BM matrix 
proteins may have been secreted by nearby VECs. From 
day 7, the PECAM-1+ VECs (Fig. 3N) with associated 
 perlecan+ BM (Fig. 3M) were found to invade the islet cell 
mass, suggesting the formation of intraislet blood vessels 
(Fig. 3O). This process was accompanied by interruption 
of the peri-islet PECAM-1 staining (Fig. 3N). By day 10, 
perlecan staining showed both peri-islet and intraislet BM 
localization (Fig. 3P); however, costaining with PECAM-1 
was restricted only to intraislet vascular endothelial BM 
(Fig. 3Q, R). Importantly, at this point, the preserved peri-
islet staining for perlecan (Fig. 3P) at day 10, as well as 
for collagen type IV (Fig. 2U), laminin a2 (Fig. 2V), and 
components of EHS laminin 111 (Fig. 2W) and nidogen-2 
(Fig. 2X), characterized the complete recovery of the islet 
BM and resembled the islet BM in situ in the pancreas 
(Figs. 1A, B; 2A−D; and 3A). These findings indicate that 
full recovery of the islet BM of transplanted islets occurs 
by 10 days after transplantation.
Islet b-cells Do Not Produce BM Matrix Proteins
To further determine the source of ECM proteins 
that form the islet BM, we investigated by flow cytom-
etry whether b-cells isolated from CBA islets produced 
matrix proteins (Fig. 4). Matrix-producing PFHR-9 cells 
showed strong intracellular staining for components of 
EHS laminin 111 (mean GMFR, 29.1 ± 4.0) (Fig. 4A), col-
lagen type IV (mean GMFR, 7.5 ± 0.9) (Fig. 4B), perle-
can (mean GMFR, 6.9 ± 0.6) (Fig. 4D) but stained weakly 
for nidogen-2 (mean GMFR, 1.7 ± 0.4) (Fig. 4C). These 
same matrix proteins were not detected in isolated b-cells 
above background levels obtained with isotype control 
IgG (GMFRs ~1) (Fig. 4A–D).
The Status of Islet and Vascular Endothelial BMs in Islet 
Allografts During Rejection
Figure 5 shows that compared with islet isografts, 
which consisted of intact islet tissue (Fig. 5A, G, P), islet 
allografts showed peri-islet accumulation of host MNCs by 
5 days (Fig. 5M) and intraislet MNC invasion by 7 days 
(Fig. 5S). Like CBA and C57BL/6 islet isografts at day 3 
(Fig. 3G–I and Fig. 5B, C, respectively), peri-islet deposi-
tion of perlecan correlated with localization of PECAM-1+ 
VECs in CBA islet allografts at 3 days after transplanta-
tion to C57BL/6 recipient mice (Fig. 5E, F). The peri-islet 
and intraislet staining for perlecan in islet allografts at 
day 5 (Fig. 5K) resembled the corresponding islet isografts 
(Fig. 5H), with the exception of prominent perlecan-positive 
vessel-like structures at the islet periphery in islet allografts 
(Fig. 5K), suggesting the formation of peri-islet blood ves-
sels. However, the staining for PECAM-1 differed mark-
edly between iso- and allografts at day 5 (Fig. 5I, L, O) 
and day 7 (Fig. 5R, U). Whereas C57BL/6 islet isografts 
showed predominantly peri-islet PECAM-1 staining as 
well as intraislet staining (Fig. 5I), peri-islet PECAM-1 
staining within islet allografts was weak (Fig. 5L) or less 
prominent (Fig. 5O). The decline in PECAM-1 expres-
sion correlated with the local accumulation of MNCs at the 
graft site (Fig. 5M). Patent peri-islet blood vessels contain-
ing MNCs were evident at day 5 (Fig. 5M–O) and day 7 
(Fig. 5S–U), but intraislet vasculature was not identified 
(Fig. 5L, O, U). Islets damaged by MNC infiltration at day 7 
also exhibited peri-islet perlecan staining, which correlated 
with PECAM-1-positive VECs. In addition, diffuse stain-
ing for perlecan was localized at extraislet sites for both 
iso- and allografts (Fig. 5H, K, Q) and is consistent with the 
extra islet deposition of collagen type IV and EHS laminin 
(Fig. 2M, O) within the graft site. These findings indicate 
that after islet allotransplantation, assembly of a VEC-
derived BM at the periphery of engrafted islets is initiated 
but the formation of intraislet blood vessels fails to occur. 
Although there is evidence for the formation of a peri-islet 
BM before intraislet MNC invasion (Fig. 5N), it is unclear 
from this allograft model whether a continuous BM around 
the islets is established before islet destruction occurs. In 
any case, the deposition of the BM matrix protein perlecan 
within the graft site stroma of islet allografts suggests the 
formation of an ad hoc BM-like barrier to cell migration.
To further explore the temporal relationship between 
peri-islet BM assembly and MNC infiltration into 
engrafted islets during allograft rejection, we analyzed 
allografts generated from the reverse donor and recipient 
mouse strain combination, where C57BL/6 islets trans-
planted into CBA recipient mice are rejected at a slower 
tempo (Fig. 6). By days 5–7, continuous peri-islet staining 
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for perlecan (Fig. 6B, F) was accompanied by peri-islet 
localization of PECAM-1 (Fig. 6C, G), suggesting that 
formation of a peri-islet BM was in progress. This fea-
ture correlated with a protracted rejection response and 
preservation of intact islet tissue. In addition, like CBA 
islet allografts in C57BL/6 recipient mice (Fig. 5K, L, N, 
O, T, U), the islets often showed vascular BM surround-
ing an expanded lumen (Fig. 6D), possibly reflecting 
enlarged blood vessels servicing the allograft inflam-
matory response, but intraislet vasculature was absent 
(Fig. 6B–D). Substantial perlecan and PECAM-1 stain-
ing was also observed throughout the graft site stroma 
(Fig. 6B–D, F–H), with an intense MNC infiltrate present 
by day 7 (Fig. 6E). In this islet allograft model, formation 
of a complete VEC-derived peri-islet BM appeared to be 
established in islets before the onset of intraislet MNC 
invasion and islet destruction. Nevertheless, the lack of 
intraislet blood vessels and the presence of prominent 
peri-islet vasculature were found to be consistent features 
of engrafted allogeneic islets facing imminent rejection at 
5–7 days posttransplant.
dIscussIon
This study clearly confirms that the islet BM of normal 
mouse islets present in situ in the pancreas and character-
ized by the localization of collagen type IV, laminins (com-
ponents of 111 and a2), nidogen-2, and perlecan (17) is 
destroyed during the enzymatic isolation of islets in vitro, 
with only remnants of laminin a2 remaining at the periph-
ery of the islets (Fig. 1). Although some residual BM of 
intraislet capillaries was evident in freshly isolated islets, 
the islets continued to lose much of their intraislet vas-
cular BM during 4 days of culture. Despite this, residual 
PECAM-1+ VECs were found adjacent to scattered sites 
of diffuse staining for intraislet perlecan. This finding is 
consistent with previous studies demonstrating matrix pro-
tein production by VECs in situ (27,28) and the substantial 
loss of intraislet VECs during culture (29). Nevertheless, 
the islet BM did not recover in vitro because no peri-islet 
staining for perlecan, collagen type IV, or laminin a2 was 
observed after maintaining the islets in culture for either 4 
days (Fig. 1) or 7 days. This finding is in disagreement with 
a previous report that islets regain their BM in culture, as 
assessed by the reappearance of reticulin staining around 
the islet periphery (54). We attribute this different inter-
pretation to the lack of specificity of silver-based reticulin 
staining for BM matrix proteins and the more likely detec-
tion of a fibroblast capsule around the islets using this 
approach (3,39).
We found that the islet BM was reestablished in vivo 
after islet transplantation. Assembly of a peri-islet BM 
was well underway by as early as 3 days posttransplant 
and was characterized by prominent, discontinuous stain-
ing for collagen type IV, components of EHS laminin 
111, nidogen-2, and perlecan (Figs. 2 and 3). Continuity 
of the peri-islet BM staining was generally established 
by 5 days posttransplantation (Figs. 2 and 3) but uninter-
rupted peri-islet laminin a2 staining was not established 
until day 10 (Fig. 2), by which time the peri-islet BM had 
undergone further remodeling, with the staining profile 
of the engrafted islets resembling islets in situ in the pan-
creas. Flow cytometry analyses of isolated islet b-cells 
failed to detect intracellular levels of BM matrix proteins 
(Fig. 4), thereby ruling out the islet cells as the source of 
ECM proteins for BM recovery. Instead, peri-islet depo-
sition of BM matrix proteins coincided with the localiza-
tion of PECAM-1-positive VECs that had migrated to the 
periphery of the islets (Fig. 3) by 3–5 days posttransplant. 
At 5 days, in particular, the peri-islet staining for collagen 
type IV, components of EHS laminin 111, nidogen-2, and 
perlecan was widespread and extended beyond the islet 
boundary into the surrounding stroma of the graft site. 
Together, these findings suggested that the peri-islet BM 
matrix proteins were most likely secreted by the VECs, a 
recognized property of VECs (27,28). Molecular remod-
eling of the ECM proteins could then lead to the forma-
tion of a peri-islet BM resembling a protective “shell” 
around the islets. From 7 to 10 days posttransplant, the 
PECAM-1 staining no longer coincided with the peri-
islet BM and instead colocalized with intraislet BM, 
consistent with the migration of VECs into the islets and 
with the formation of intraislet vascular endothelium. The 
separation of the peri-islet BM and PECAM-1+ VECs 
marked the reestablishment of the independent islet BM, 
albeit most likely VEC-derived, and probably represents 
another example of how migrating or regressing VECs 
can abandon the BM that they deposit (24,28).
The origin of the VECs potentially responsible for the 
recovery of the islet BM is unclear. An isolated region 
of VECs and subendothelial BM was identified within 
some engrafted islets as early as 3 days posttransplant 
(Figs. 2 and 3) but was not observed by 5 days, suggesting 
FAcInG PAGe
Figure 4. Isolated islet b-cells do not produce BM matrix proteins. Intracellular staining for BM matrix proteins was assessed by 
flow cytometry in control mouse embryonal carcinoma (PFHR-9) cells (A–E) and in isolated CBA islet b-cells (A–E). The solid line 
in A to D shows the staining with primary rabbit anti-mouse (A) EHS laminin, (B) collagen type IV, (C) nidogen-2, and (D) perlecan 
polyclonal antibody (pAb), and the dotted line shows the background staining obtained with an isotype control rabbit IgG. The data in 
(E) show the mean GMFR ± SEM for EHS laminin, collagen type IV, nidogen-2, and perlecan staining in b-cells and PFHR-9 cells 
from n = 4–5 independent experiments. *p = 0.0079; **p = 0.0286, compared with control PFHR-9 cells.
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Figure 5. Recovery of peri-islet BM perlecan occurs without the formation of intraislet blood vessels in rejecting islet allografts. 
C57BL/6 islet isografts and CBA islet allografts in C57BL/6 recipient mice at 3–7 days after transplantation beneath the kidney cap-
sule were examined by dual immunofluorescence staining of sections for perlecan (B, E, H, K, Q, T) and PECAM-1 (C, F, I, L, R, U), 
and laminin (N) and PECAM-1 (O). H&E-stained serial sections of immunolabeled islets are also shown (A, D, G, J, M, P, S). Host 
mononuclear cells (MNCs) were found to accumulate around intragraft islets by 5 days (M, region indicated by stars) and were present 
in prominent vessel lumens at the periphery of islets (asterisk in M–O, S–U). Arrows indicate prominent blood vessels; open arrows 
indicate the peri-islet BM. Nuclei are counterstained blue with DAPI. Scale bars: 25mm.
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that these intraislet VECs may have migrated to the islet 
periphery. However, other studies have reported that 
transplanted islets are revascularized predominantly by 
endothelium of recipient origin (7,25,52), with donor-
type VECs remaining after islet isolation, also contrib-
uting to the process (5,19,29). b-Cells produce vascular 
endothelial growth factor (VEGF-A) (7), which could 
recruit host VECs to the graft site and to the periphery 
of transplanted islets (22). It is therefore possible that 
both host and residual donor VECs play a critical role in 
repairing the BMs of engrafted islets.
The matrix detachment of islet cells resulting from 
loss of the islet BM during islet isolation and the quick 
onset of the islet BM recovery process in vivo after trans-
plantation is offset to some extent by a staggered loss of 
intraislet vasculature after islet isolation and a relatively 
slow process of islet revascularization. This asynchrony 
between the loss and recovery of the peri- and intraislet 
BMs may ensure that islet cells are not completely devoid 
of matrix attachment during engraftment, a property that 
would promote b-cell survival. Nevertheless, we have 
observed that the BM remodeling process proceeds over 
a period of 7 to 10 days, suggesting that at least some 
matrix detachment-induced b-cell apoptosis (41,50,51,55) 
is likely. This would be expected to compound the b-cell 
apoptosis induced by loss of intracellular heparan sulfate 
in the b-cells during islet isolation (57). Our findings 
therefore support the notion of cotransplanting VEC/mes-
enchymal stem cell (MSC) mixtures (20) with isolated 
islets, not only to facilitate more rapid revascularization 
of the engrafted islets (6) to actively provide nutrients and 
oxygen for b-cell metabolism and function but also to 
more promptly establish peri- and intraislet BM recovery 
and matrix reattachment. The restoration of b-cell–matrix 
interactions would be expected to provide major benefits 
to islet survival and function, as previously demonstrated 
in vitro (13,21,27,34,56) and in vivo (42), and to mini-
mize primary islet loss in a transplant setting.
In the situation of islet allotransplantation, we found 
that, initially, the remodeling of the peri-islet BM, as 
revealed by perlecan localization, resembled the pattern 
for islet isografts (Fig. 5). However, in contrast to the peri-
islet PECAM-1+ staining observed at 3 days after allotrans-
plantation, very little peri-islet PECAM-1 staining was 
observed at 5–7 days in the CBA to C57BL/6 mouse strain 
combination in which aggressive islet destruction by infil-
trating MNCs occurs because of allograft rejection (Fig. 5). 
In comparison, peri-islet PECAM-1 staining was observed 
at 7 days in the reverse C57BL/6 to CBA mouse strain 
combination where islet destruction is routinely delayed 
because of a slower tempo of rejection (Fig. 6). Indeed, 
this low level of PECAM-1 staining is probably due to the 
Figure 6. Reestablishment of peri-islet BM perlecan is accompanied by peri-islet migration of PECAM-1+ endothelial cells in reject-
ing islet allografts. C57BL/6 islet allografts at 5 (A–D) and 7 (E–H) days posttransplant to CBA mice were analyzed by immunofluo-
rescence staining for perlecan (red fluorescence) and PECAM-1 (green fluorescence). The merged images show yellow fluorescence, 
revealing the colocalization of perlecan and PECAM-1 staining around the periphery of islets. Arrows identify enlarged peri-islet 
blood vessels. Perlecan staining is also strongly expressed and diffusely distributed throughout the graft site (B, F). H&E-stained serial 
sections (A, E) of the immunostained islets reveal the presence of intact islet tissue, despite an intense MNC infiltrate at the graft site. 
Nuclei are counterstained blue with DAPI. Scale bar: 25 mm.
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downregulation of PECAM-1 expression by cytokines pro-
duced by nearby invading MNCs, as previously reported 
(26,49), and to mouse strain-specific effects, rather than 
the loss of VECs. A striking difference between the isograft 
(Figs. 3 and 5) and allograft (Figs. 5 and 6) models, how-
ever, with both mouse strain combinations, was the con-
sistent lack of intraislet vascular BMs in the allografts by 
day 7. Instead, the allografts were characterized by an abun-
dance of peri-islet and intragraft perlecan+ BMs (Figs. 5 
and 6) and the colocalization of PECAM-1+ endothelial 
cells (Fig. 6), consistent with increased vascularization of 
the graft site during rejection. Indeed, the profuse peri-islet 
vasculature was found to contain nucleated DAPI+ cells, 
consistent with the delivery of MNCs to the engrafted islets 
(Fig. 5N, O, T, and U). Together, these findings suggest 
that although VECs initially commence the deposition of 
peri-islet BMs in islet allografts, the cue for the formation 
of intraislet vasculature fails to occur, and instead, VECs 
are diverted to enhance the peri-islet and intragraft vascu-
lature required to transport activated alloreactive T cells to 
the engrafted donor islet tissue. The factors that regulate 
this change may involve inflammatory cytokines (32) and/
or chemokines (48). In the context of an allograft rejection 
response, it is likely that such VECs would be of host ori-
gin and that the increased peri-islet vasculature and vaso-
dilation could facilitate MNC delivery to the transplanted 
islets, as previously described for sites of acute inflamma-
tion (38). In contrast to islet isografts, we therefore predict 
that in an allograft setting without adequate immune pro-
tection, the cotransplantation of exogenous VECs/MSCs to 
facilitate islet revascularization (20) may well induce the 
undesired effect of accelerating allograft rejection.
We propose that the effector mechanisms required 
by infiltrating MNCs to enter engrafted allogeneic islets 
are likely to be substantially influenced by the presence 
or absence of an islet BM. We have previously reported 
that insulitis MNCs critically require the heparan sulfate-
degrading enzyme heparanase to solubilize and traverse 
the islet BM in NOD/Lt islets in situ to initiate destructive 
insulitis and the development of autoimmune diabetes 
(57). Similarly, the islet BM of engrafted allogeneic islets 
as well as the excessive levels of perlecan+ ECM that we 
observed within islet allograft sites would be expected to 
act as formidable barriers to intraislet MNC infiltration 
and intragraft migration during the allograft rejection 
response (33,47,57). The production of matrix-degrading 
enzymes such as heparanase by infiltrating host MNCs 
could circumvent this problem and potentially repre-
sent a novel drug target for anti-graft rejection therapy. 
Conversely, BM-deficient islets would be expected to be 
at a heightened risk of immune destruction.
In this study of islet BM matrix proteins, we revealed 
complete loss of the islet BM after islet isolation and a 
transient absence of a conventional islet BM and intraislet 
subvascular endothelial BM early after transplantation, 
which together highlight a period of islet vulnerability and 
increased risk of b-cell loss due to ECM detachment. We 
further identify critical roles for VEC migration and sub-
endothelial BM remodeling in the reassembly of the islet 
BM in islet isografts and allografts and in the restoration 
of intraislet vasculature and b-cell–matrix attachment in 
islet isografts. We discovered that intraislet BMs fail to 
recover in islet allografts and postulate that prolonged 
matrix detachment from both peri- and intraislet BMs 
may negatively impact the survival of islet b-cells, sup-
plementing MNC-mediated destruction of islet allografts 
in the absence of antirejection therapy. These findings 
strongly support the critical need for the islet BMs to be 
preserved during islet isolation. Potential benefits would 
include improvement in b-cell viability due to the main-
tenance of b-cell–matrix attachment, the possibility of 
more efficient revascularization of the engrafted islets, 
and the retention of a local BM barrier protection of allo-
geneic islets against cell invasion. Our studies identify 
the islet BM as a critical biomarker for islet integrity and 
predict that islet BM analysis after enzymatic isolation 
could be an effective measure for evaluating optimal 
enzyme preparations/combinations, particularly for clini-
cal islet transplantation.
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